Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Trusopt: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Trusopt - General Information

Trusopt is a carbonic anhydrase inhibitor. It is used in ophthalmic solutions (Trusopt) to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.

 

Pharmacology of Trusopt

Trusopt is topical carbonic anhydrase inhibitor. Trusopt is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.

 

Trusopt for patients

Dorzolamide is a sulfonamide and although administered topically is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. Patients should be advised that if serious or unusual reactions or signs of hypersensitivity occur, they should discontinue the use of the product.

Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and lid reactions, they should discontinue use and seek their physician's advice.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

 

Trusopt Interactions

Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.

 

Trusopt Contraindications

Dorzolamide is contraindicated in patients who are hypersensitive to any component of this product.

 

Additional information about Trusopt

Trusopt Indication

For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma

Mechanism Of Action
Trusopt is a sulfonamide and a human carbonic anhydrase II inhibitor. Inhibition of carbonic anhydrase II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Generic Name
Dorzolamide
Drug Category
Antihypertensive Agents; Carbonic Anhydrase Inhibitors
Drug Type
Small Molecule; Approved
Other Brand Names containing Dorzolamide
Trusopt;
Toxicity (Overdose)
Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest
Protein Binding
~33%
Half Life
4 months
Dosage Forms of Trusopt
Solution Ophthalmic
Chemical IUPAC Name
4-ethylamino-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[5,4-b]thiopyran-2-sulfonamide
Chemical Formula
C10H16N2O4S3
Organisms Affected
Humans and other mammals